Applied BioCode (6598) — Capital Reinvestment Ratio
Latest as of September 2022:
1.89x
Applied BioCode (6598) has a Capital Reinvestment Ratio of 1.89x as of September 2022, meaning it reinvests 2% of its operating cash flow (NT$6.35 Million) in capital expenditures (NT$12.00 Million). See 6598 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
1.89x
Capex / Operating Cash Flow
Operating Cash Flow
NT$6.35 Million
TWD
Capital Expenditures
NT$12.00 Million
TWD
Data as of
Sep 2022
Most recent filing
Applied BioCode Capital Reinvestment Ratio (2022–2022)
This chart tracks Applied BioCode's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Applied BioCode (2022–2022)
Year-by-year Capital Reinvestment Ratio for Applied BioCode from 2022 to 2022. For live market cap and broader valuation context, see 6598 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.15x | NT$145.87 Million | NT$22.14 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow